







an Open Access Journal by MDPI

Gene-Based Vaccines

Guest Editor:

Dr. Michael A. Barry

Department of Medicine, Mayo Clinic, Rochester, MN 55902, USA

Deadline for manuscript submissions:

closed (31 August 2022)

Message from the Guest Editor

The COVID-19 pandemic has brought gene-based vaccines into the forefront of human medicine, whether they be mRNA vaccines or DNA-based vaccines. This issue will examine the biology, application, immunology, and practical aspects of using gene-based vaccines for many pathogens, including SARS-CoV-2.













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with <u>article processing charges (APC)</u> paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us